| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2010-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103003278-B |
| titleOfInvention |
Aryl amine purine derivative and preparation method thereof and in purposes pharmaceutically |
| abstract |
Disclose aryl amine purine derivative shown in formula I and preparation method thereof, wherein each substituting group as in specification sheets define.The nonsmall-cell lung cancer of this compound to the sudden change of EGF-R ELISA (EGFR) 19 Exon deletion or 21 exon L858R point mutation is inhibited. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107892691-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107892691-B |
| priorityDate |
2010-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |